Effect of premorbid beta-blockers on cardiac function and clinical outcomes in septic patients: a retrospective study
By: Siyu Yang, Rongyao Feng, Xiangzhou Fang and Chaojie Wei
References
- Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801.
- Fleischmann-Struzek C, Mellhammar L, Rose N, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020 Aug;46(8):1552–62.
- Beesley SJ, Weber G, Sarge T, et al. Septic Cardiomyopathy. Crit Care Med. 2018 Apr;46(4):625–34.
- Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. 2021 Jun;18(6):424–34.
- Poveda-Jaramillo R. Heart Dysfunction in Sepsis. J Cardiothorac Vasc Anesth. 2021 Jan;35(1):298–309.
- Pathan N, Franklin JL, Eleftherohorinou H, Wright VJ, Hemingway CA, Waddell SJ, et al. Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase. Crit Care Med. 2011 Jul;39(7):1692–711.
- Wang L, Li Y, Wang X, Wang P, Essandoh K, Cui S, et al. GDF3 Protects Mice against Sepsis-Induced Cardiac Dysfunction and Mortality by Suppression of Macrophage Pro-Inflammatory Phenotype. Cells. 2020 Jan 3;9(1):120.
- Sharawy N, Lehmann C. Molecular mechanisms by which iNOS uncoupling can induce cardiovascular dysfunction during sepsis: Role of posttranslational modifications (PTMs). Life Sci. 2020 Aug 15;255:117821.
- Mokhtari B, Hamidi M, Badalzadeh R, Mahmoodpoor A. Mitochondrial transplantation protects against sepsis-induced myocardial dysfunction by modulating mitochondrial biogenesis and fission/fusion and inflammatory response. Mol Biol Rep. 2023 Mar;50(3):2147–58.
- Martin L, Horst K, Chiazza F, Oggero S, Collino M, Brandenburg K, et al. The synthetic antimicrobial peptide 19-2.5 attenuates septic cardiomyopathy and prevents down-regulation of SERCA2 in polymicrobial sepsis. Sci Rep. 2016 Nov 17;6:37277.
- Vasques-Nóvoa F, Laundos TL, Madureira A, Bettencourt N, Nunes JPL, Carneiro F, et al. Myocardial Edema: an Overlooked Mechanism of Septic Cardiomyopathy? Shock. 2020 May;53(5):616–9.
- Stewart RH, Cox CS, Allen SJ, Laine GA. Myocardial Edema Provides a Link Between Pulmonary Arterial Hypertension and Pericardial Effusion. Circulation. 2022 Mar 15;145(11):793–5.
- Carbone F, Liberale L, Preda A, Schindler TH, Montecucco F. Septic Cardiomyopathy: From Pathophysiology to the Clinical Setting. Cells. 2022 Sep 11;11(18):2833.
- Dal-Secco D, DalBó S, Lautherbach NES, Gava FN, Celes MRN, Benedet PO, et al. Cardiac hyporesponsiveness in severe sepsis is associated with nitric oxide-dependent activation of G protein receptor kinase. Am J Physiol Heart Circ Physiol. 2017 Jul 1;313(1):H149–63.
- Rehman A, Baloch NUA, Morrow JP, Pacher P, Haskó G. Targeting of G-protein coupled receptors in sepsis. Pharmacol Ther. 2020 Jul;211:107529.
- Stolk RF, van der Pasch E, Naumann F, Schouwstra J, Bressers S, van Herwaarden AE, et al. Norepinephrine Dysregulates the Immune Response and Compromises Host Defense during Sepsis. Am J Respir Crit Care Med. 2020 Sep 15;202(6):830–42.
- Kimmoun A, Louis H, Al Kattani N, Delemazure J, Dessales N, Wei C, et al. β1-Adrenergic Inhibition Improves Cardiac and Vascular Function in Experimental Septic Shock*: Critical Care Medicine. 2015 Sep;43(9):e332–40.
- Wei C, Al Kattani N, Louis H, Albuisson E, Levy B, Kimmoun A. If Channel Inhibition With Ivabradine Does Not Improve Cardiac and Vascular Function in Experimental Septic Shock. Shock. 2016 Sep;46(3):297–303.
- Wei C, Louis H, Schmitt M, Albuisson E, Orlowski S, Levy B, et al. Effects of low doses of esmolol on cardiac and vascular function in experimental septic shock. Crit Care. 2016 Dec 21;20(1):407.
- Ma Y, Cheng Z, Zheng Y, Wang W, He S, Zhou X, et al. LOW DOSE OF ESMOLOL ATTENUATES SEPSIS-INDUCED IMMUNOSUPPRESSION VIA MODULATING T-LYMPHOCYTE APOPTOSIS AND DIFFERENTIATION. Shock. 2023 May 1;59(5):771–8.
- Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013 Oct 23;310(16):1683–91.
- Kuo MJ, Chou RH, Lu YW, Guo JY, Tsai YL, Wu CH, et al. Premorbid β1-selective (but not non-selective) β-blocker exposure reduces intensive care unit mortality among septic patients. J Intensive Care. 2021 May 13;9(1):40.
- Macchia A, Romero M, Comignani PD, Mariani J, D'Ettorre A, Prini N, et al. Previous prescription of β-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis*: Critical Care Medicine. 2012 Oct;40(10):2768–72.
- Christensen S, Johansen MB, Tønnesen E, Larsson A, Pedersen L, Lemeshow S, et al. Preadmission beta-blocker use and 30- day mortality among patients in intensive care: a cohort study. Crit Care. 2011;15(2):R87.
- Singer KE, Collins CE, Flahive JM, Wyman AS, Ayturk MD, Santry HP. Outpatient beta-blockers and survival from sepsis: Results from a national cohort of Medicare beneficiaries. Am J Surg. 2017 Oct;214(4):577–82.
- Leyrat C, Seaman SR, White IR, Douglas I, Smeeth L, Kim J, et al. Propensity score analysis with partially observed covariates: How should multiple imputation be used? Stat Methods Med Res. 2019 Jan;28(1):3–19.
- Bosmann M, Ward PA. The inflammatory response in sepsis. Trends Immunol. 2013 Mar;34(3):129–36.
- Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017 Jul;39(5):517–28.
- Fuchs C, Wauschkuhn S, Scheer C, Vollmer M, Meissner K, Kuhn SO, et al. Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. British Journal of Anaesthesia. 2017 Oct;119(4):616–25.
- Abdalla M, Sohal S, Al-Azzam B, Mohamed W. Effect of Troponin I Elevation on Duration of Mechanical Ventilation and Length of Intensive Care Unit Stay in Patients With Sepsis. J Clin Med Res. 2019 Feb;11(2):127–32.
- Yu H, Yang Q, Qian Y, Luo S, Kong T, Yang G, et al. A positive correlation between serum lactate dehydrogenase level and in-hospital mortality in ICU sepsis patients: evidence from two large databases. Eur J Med Res. 2024 Nov 1;29(1):525.
- He B, Wang X, Shi L, Cheng H, Zhao L. Meta-analysis of initial natriuretic peptides in the setting of sepsis-induced myocardial dysfunction. Biomark Med. 2024 Feb;18(4):145–55.
- Post F, Weilemann LS, Messow CM, Sinning C, Münzel T. B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients. Crit Care Med. 2008 Nov;36(11):3030–7.
- Yue L, Deng X, Yang M, Li X. Elevated B-type natriuretic peptide (BNP) and soluble thrombomodulin (sTM) indicates severity and poor prognosis of sepsis. Ann Palliat Med. 2021 May;10(5):5561–7.
- Khoury J, Arow M, Elias A, Makhoul BF, Berger G, Kaplan M, et al. The prognostic value of brain natriuretic peptide (BNP) in non-cardiac patients with sepsis, ultra-long follow-up. J Crit Care. 2017 Dec;42:117–22.
- Kim JS, Kim M, Kim YJ, Ryoo SM, Sohn CH, Ahn S, et al. Troponin Testing for Assessing Sepsis-Induced Myocardial Dysfunction in Patients with Septic Shock. J Clin Med. 2019 Feb 12;8(2):239.
- Zheng P, Wang X, Guo T, Gao W, Huang Q, Yang J, et al. Cardiac troponin as a prognosticator of mortality in patients with sepsis: A systematic review and meta-analysis. Immun Inflamm Dis. 2023 Sep;11(9):e1014.
- Dugar S, Sato R, Chawla S, You JY, Wang X, Grimm R, et al. Is Left Ventricular Systolic Dysfunction Associated With Increased Mortality Among Patients With Sepsis and Septic Shock? Chest. 2023 Jun;163(6):1437–47.
- Clancy DJ, Scully T, Slama M, Huang S, McLean AS, Orde SR. Application of updated guidelines on diastolic dysfunction in patients with severe sepsis and septic shock. Ann Intensive Care. 2017 Dec 19;7(1):121.
- Lanspa MJ, Cirulis MM, Wiley BM, Olsen TD, Wilson EL, Beesley SJ, et al. Right Ventricular Dysfunction in Early Sepsis and Septic Shock. Chest. 2021 Mar;159(3):1055–63.
- Tan S, Zhou F, Zhang Z, Wang J, Xu J, Zhuang Q, et al. Beta-1 blocker reduces inflammation and preserves intestinal barrier function after open abdominal surgery. Surgery. 2021 Apr;169(4):885–93.
- Kumar S, Malviya D, Tripathi M, Rai S, Nath SS, Tripathi SS, et al. Exploring the Impact of Prior Beta-Blocker and Calcium Channel Blocker Usage on Clinical Outcomes in Critically Ill Patients With Sepsis: An Observational Study. Cureus. 2023 Sep;15(9):e46169.
- Tan K, Harazim M, Simpson A, Tan YC, Gunawan G, Robledo KP, et al. Association Between Premorbid Beta-Blocker Exposure and Sepsis Outcomes-The Beta-Blockers in European and Australian/American Septic Patients (BEAST) Study. Crit Care Med. 2021 Sep 1;49(9):1493–503.
- Tan K, Harazim M, Tang B, Mclean A, Nalos M. Correction to: The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review. Crit Care. 2020 Jan 3;24(1):3.
- McLean AS, Taccone FS, Vieillard-Baron A. Beta-blockers in septic shock to optimize hemodynamics? No. Intensive Care Med. 2016 Oct;42(10):1610–2.
- Hong SY, Lai CC, Teng NC, Chen CH, Hsu CC, Chan NJ, et al. Premorbid use of selective beta-blockers improves sepsis incidence and course: Human cohort and animal model studies. Front Med (Lausanne). 2023;10:1105894.
Language: English
Page range: 271 - 280
Submitted on: Nov 1, 2025
Accepted on: Feb 12, 2026
Published on: Apr 30, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Siyu Yang, Rongyao Feng, Xiangzhou Fang, Chaojie Wei, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.